TIMOTHY SOUTH: Open Payments
NPI 1376506741 · KOSCIUSKO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$874 in 41 payments from 10 companies in 2025. Trend: 2023 $1,341 · 2024 $1,465 · 2025 $874
Food & beverage: $874
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $364 |
| Novo Nordisk Inc | 10 | $171 |
| PFIZER INC. | 4 | $75 |
| ABBVIE INC. | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $60 |
| GlaxoSmithKline, LLC. | 3 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
| Averitas Pharma Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
Products named: AIRSUPRA, BREZTRI, Ozempic, REXULTI, TRELEGY ELLIPTA, PREVNAR 20, Rybelsus, UBRELVY.
Industry payments across MS — which companies pay providers there.
